Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
8,564 total articles
Nano Labs has shifted strategy in 2025 from fabless chip growth to building crypto reserves (primarily BNB) while slashing operating costs. The move compresses traditional revenue growth prospects but creates an asymmetric trade: a low current market cap ($73.8M) and insider buying versus weak recent revenue and a pivot-dependent thesis. I lay out …
Netskope plunged after a guidance-driven sell-off, but fundamentals remain intact: 33% reported sales growth, 118% net retention, new AI-enabled product launches and enterprise tailwinds for SASE. At a $3.64B market cap and deeply oversold technicals (RSI ~22), this dip is an asymmetric trade. Aggressive buyers can establish a position at $9.29 wit…
Hims & Hers (HIMS) has been hammered by an FDA crackdown and a patent suit tied to its copycat GLP-1 pill, sending the stock to 52-week lows. The sell-off appears disproportionate relative to a still-profitable telehealth core: $3.54B market cap, positive free cash flow, and a leverageable acquisition pipeline. This trade idea lays out a mid-term (…
Nuveen New York Quality Municipal Income Fund (NAN) is trading near the top of its 52‑week range with strong short activity and limited near‑term dividend support. For traders willing to accept elevated risk, a mid‑term short targeting mean reversion to the low end of the range offers an asymmetric payoff with defined entry, stop and target.
Acadia Healthcare is a beaten-down behavioral-health operator trading at value multiples while short interest sits above 30% of the float. With bullish momentum, activist ownership, and litigation clarity possible, this is a tactical long with a clearly defined stop and mid-term horizon to capture a potential short squeeze and re-rating.
Archer Aviation (ACHR) is a pre-revenue eVTOL maker with a $5.1B market cap that just secured a concrete operating plan tied to LA28 through its Hawthorne Airport deal. That operational foothold, combined with a large institutional stake and improving technicals, creates a tradeable long with a defined entry, stop and target for a long-term (180 tr…
Nebius (NEBIUS) appears to be trading on momentum and narrative gaps rather than underlying business progress. With no options market and limited public disclosure, the risk/reward favors a measured short. This trade idea lays out a concrete entry at $6.50, an immediate stop at $9.00, and a primary target of $3.50 across a 45-trading-day swing hori…
Tesla is actively shifting capital and strategic focus away from legacy vehicle profit-per-unit toward recurring, software-driven revenue streams anchored by Dojo, FSD/robotaxi, and energy/software services. This trade buys that transition at a tactical entry with defined stop and ambitious target that prices in accelerating AI monetization.
Uber's stock is trading well below its 52-week high despite healthy free cash flow, improving profitability and concrete growth catalysts (autonomy, European delivery expansion). Market uncertainty has compressed the multiple; we present a staged long trade with defined entry, stop and target that balances upside with near-term volatility risks.
Travere's FILSPARI (sparsentan) is now the center of the company's revenue story and a near-term regulatory binary that could re-rate the stock. At $30.75 the fundamentals and technicals suggest a tactical long: entry at $30.50, stop at $25.00, and a target at $42.00 tied to prior highs and potential approval/launch upside.
<p>American Shared Hospital Services (AMS) looks mispriced. Recent headlines around automation and AI replacing clinical services have pushed sentiment lower for capital-intensive, people-driven treatment providers. That worry is misplaced for a company that leases Gamma Knife and other radiosurgery equipment, reported 17% revenue growth in Q1 2025…
AST SpaceMobile has cleared a major technology hurdle with BlueBird 6 and is rapidly funding a constellation buildout. The stock already prices ambitious telecom partnerships and global coverage. This trade idea lays out a disciplined long entry at $84.38, a $120 target, and a $60 stop for a long-term push as the company moves from validation to de…
Nebius Group (NBIS) has been punished recently alongside other capital-intensive AI-infrastructure names, but the company’s large backlog, hyperscaler contracts and operational momentum argue for a tactically constructive trade. This idea lays out an entry at $100.58, a stop at $85.00 and a target at $140.00 for a long-term position (180 trading da…
Flowserve delivered the kind of operating leverage investors want to see: improving margins, meaningful free cash flow and order-book exposure to secular pump and valve markets. At a market cap near $11.2B, free cash flow of $435M and a 52-week high of $91.31, FLS offers a pragmatic long trade with defined risk and catalysts that can unlock upside …
Nebius Group has moved from pure-capex risk to a hybrid model where large hyperscaler contracts and customer-funded capacity materially change the balance of returns vs. risk. At $100.70 today and a $25.3B market cap, the stock is richly priced, but near-term catalysts and a sizable backlog give a path to justify upside. This trade idea outlines a …
Sprott Inc. reported a 146% earnings jump that validates my operational leverage thesis: fee-bearing exchange-listed products and balance-sheet lending are scaling faster than incremental costs. Combine that with recent trust-level initiatives, a higher quarterly dividend and positive commodity flows and you get a tradeable long with defined entry,…
Daiichi Sankyo has taken blows recently from regulatory and commercial setbacks, but the company’s diversified oncology and cardiovascular franchises, plus sizable biologics manufacturing capabilities, create a path to recovery. The sell-off looks disproportionate to the underlying value of the pipeline and manufacturing assets. This trade idea out…
Main Street Capital (MAIN) offers a high single-digit yield with a conservative balance sheet, reasonable valuation and an attractive entry after a recent pullback. For investors looking to complement bond holdings with equity income and modest capital upside, MAIN provides a trade-able setup with clear entry, stop and target.
Nebius is executing a blitz buildout of GPU-powered data centers and is benefiting from outsized hyperscaler spending. Revenue and ARR trajectories look explosive on paper, but high valuation and capital intensity make this a high-risk, high-reward swing trade. Entry, target, and stop are provided with a 45-trading-day horizon and explicit risks to…
Celsius has stabilized after the post-inventory shake-up with PepsiCo and shows signs of re-accelerating revenue and cash generation. The market is pricing strong growth into the stock (market cap ~$12.7B), but near-term technicals and improving fundamentals create a practical swing trade with defined risk.
Danaos (DAC) is trading near $108 but sits on a $4.3 billion contracted revenue backlog, reported adjusted EPS of $7.14 in Q4 2025 and holds $1.4 billion of liquidity. Management is returning capital aggressively while expanding contracted coverage and the fleet. Given a cheap multiple (PE ~4.1, PB ~0.54) and improving technical momentum, this trad…
Shinhan Financial (SHG) is trading near $69.93 with strong technical momentum, single-digit P/E and sub-1.0 P/B. With management emphasizing shareholder returns and a clear path to lift ROE, the stock looks actionable for a medium-term swing: enter at $69.93, stop $66.00, target $77.00. Key risks include elevated short activity, near-term overbough…
Amazon's recent pullback prices in a higher capex run that will depress free cash flow near term. But with AWS profitability, healthy ROE, a reasonable P/S multiple and technical oversold conditions, a long trade at current levels offers asymmetric upside. This idea lays out an entry, stop and target for a 180-trading-day trade and a clear checklis…
Pliant Therapeutics is a highly discounted clinical-stage biotech trading at roughly $76M market cap. The stock has been depressed by a paused BEACON-IPF trial and investor litigation, but an upcoming or recent lapse of a shareholder rights plan (poison pill) could allow strategic buyers to accumulate and force a revaluation. This trade idea buys t…
Booking Holdings is trading at a 52-week low after a steep pullback driven by AI disruption fears. The company's scale across Booking.com, Priceline, Agoda, KAYAK and OpenTable plus improving product initiatives (connected-trip, generative-chat integrations) keep its distribution moat intact. This trade targets a rebound into higher multiples with …
